December 2015, Vol. 4, No. 6
Personalized Medicine in Oncology: Disseminating Essential Information
On behalf of all of us at Personalized Medicine in Oncology (PMO), I’d like to offer our warmest wishes to you this holiday season and our thanks for your loyal readership throughout 2015. Over this past year, we have witnessed advances in our knowledge of tumor biology, biomarkers, and immunotherapies that will ultimately improve our ability to effectively and safely treat patients with cancer.
With these advances, our editorial staff has added departments and enhanced existing ones to improve dissemination of this essential information. These include:
- Interview with the Innovators Series: In each issue, we speak with people making a difference in the field of personalized medicine. From leading researchers and novel diagnostic companies to policy makers and patient organizations, these interviews provide insights to the trends in precision medicine
- Genetic Counseling Column: 2015 saw the launch of our newest department authored by editorial board member Cristi Radford, MS, CGC, of the Moffitt Cancer Center. Ms Radford will address cutting-edge topics in this expanding field
- The Last Word: PMO is a proud partner of the Personalized Medicine Coalition (PMC) and is pleased to host a regular column by the President of the PMC, Edward Abrahams, PhD. Dr Abrahams brings expertise in the policy trends affecting our ability to provide personalized care to our patients
- PersonalizedMedOnc.com: An invaluable resource to our readers, our website includes articles from the journal as well as breaking news stories, conference correspondent highlights, special issues, and videos. I strongly encourage you to subscribe.
It is our continuing hope that our comprehensive services benefit you and ultimately your patients. Thank you for your readership and all the best to you in 2016.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Patients with early breast cancer and a low Oncotype DX Recurrence Score (RS) can be safely treated with hormone therapy alone and avoid chemotherapy, according to results from the National Cancer Institute–sponsored TAILORx trial.1,2 Patients who had an RS of <11 treated with hormone therapy alone had less than a [ Read More ]
On November 24, 2015, the FDA approved Portrazza (necitumumab) in combination with 2 forms of chemotherapy to treat patients with advanced (metastatic) squamous non–small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. Lung cancer is the leading cause of cancer death [ Read More ]